Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension - Thomas T van Sloten, Patrick C Souverein, Coen DA Stehouwer, Johanna HM Driessen, 2022
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices - ScienceDirect
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review | European Respiratory Society
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis | PLOS Computational Biology
JCM | Free Full-Text | Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking | Critical Care | Full Text
How effectively do ACE inhibitors and ARBs prevent migraines? | MDedge Family Medicine
ACE inhibitors and ARBs: Managing potassium and renal function | Cleveland Clinic Journal of Medicine
Side Effects of ACEi/ARBs During Pregnancy | Calgary Guide
RACGP - ACEIs for cardiovascular risk reduction – have we taken our eye off the ball?
Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea | Scientific Reports
Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? | SpringerLink
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension – An Update of the 2007 Report | Effective Health Care (EHC) Program
Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost‐effectiveness analysis - Wu - 2018 - Journal of Diabetes Investigation - Wiley Online Library
Cross-Reactivity of ACE Inhibitor–Induced Angioedema with ARBs
Frontiers | Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB | SpringerLink
Therapeutics Initiative | How do you prescribe ACEIs and ARBs for hypertension?
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients - Zhao - 2021 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients | eLife
ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk | Hypertension
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? | Circulation
COVID-19 and Use of Drugs Targeting the Renin-Angiotensin-System - American College of Cardiology
Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19 | Hypertension Research
